JP2024500133A5 - - Google Patents

Info

Publication number
JP2024500133A5
JP2024500133A5 JP2023537242A JP2023537242A JP2024500133A5 JP 2024500133 A5 JP2024500133 A5 JP 2024500133A5 JP 2023537242 A JP2023537242 A JP 2023537242A JP 2023537242 A JP2023537242 A JP 2023537242A JP 2024500133 A5 JP2024500133 A5 JP 2024500133A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
approximately
composition according
composition contains
chloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537242A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024500133A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/064222 external-priority patent/WO2022133324A1/en
Publication of JP2024500133A publication Critical patent/JP2024500133A/ja
Publication of JP2024500133A5 publication Critical patent/JP2024500133A5/ja
Pending legal-status Critical Current

Links

JP2023537242A 2020-12-18 2021-12-17 アデノ随伴ウイルスベクターを含む改善された医薬組成物 Pending JP2024500133A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063127826P 2020-12-18 2020-12-18
US63/127,826 2020-12-18
PCT/US2021/064222 WO2022133324A1 (en) 2020-12-18 2021-12-17 Improved pharmaceutical compositions containing adeno-associated viral vector

Publications (2)

Publication Number Publication Date
JP2024500133A JP2024500133A (ja) 2024-01-04
JP2024500133A5 true JP2024500133A5 (https=) 2026-04-02

Family

ID=79686851

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537242A Pending JP2024500133A (ja) 2020-12-18 2021-12-17 アデノ随伴ウイルスベクターを含む改善された医薬組成物

Country Status (10)

Country Link
US (1) US20240066146A1 (https=)
EP (1) EP4262754A1 (https=)
JP (1) JP2024500133A (https=)
KR (1) KR20230122076A (https=)
CN (1) CN116710149A (https=)
AU (1) AU2021403118A1 (https=)
CA (1) CA3204462A1 (https=)
IL (1) IL303737A (https=)
MX (1) MX2023006471A (https=)
WO (1) WO2022133324A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024505060A (ja) * 2021-01-27 2024-02-02 エイラ・セラピューティクス・インコーポレイテッド Ｐｎｍａ２ベースのキャプシド及びその使用
US20240307553A1 (en) * 2021-04-01 2024-09-19 Pfizer Inc. Pharmaceutical compositions containing adeno-associated viral vector
CN116350801A (zh) * 2022-11-22 2023-06-30 四川至善唯新生物科技有限公司 一种重组腺相关病毒载体的药物组合物及其用途
EP4651883A1 (en) * 2023-01-19 2025-11-26 uniQure biopharma B.V. Pharmaceutical formulations of gene delivery vehicles
WO2025045083A1 (zh) * 2023-09-01 2025-03-06 康霖生物科技（杭州）有限公司 一种液体制剂及其用途
WO2025076729A1 (zh) * 2023-10-11 2025-04-17 朗信启昇(苏州)生物制药有限公司 包含aav的药物组合物及其制备方法
WO2025108407A2 (en) * 2023-11-23 2025-05-30 Neuexcell Therapeutics (Suzhou) Co., Ltd. Gene therapy compositions and methods for treating glioma
WO2025113676A1 (en) * 2023-11-29 2025-06-05 Neuexcell Therapeutics (Suzhou) Co., Ltd. Compositions and methods for treating stroke in primates

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE226449T1 (de) * 1998-12-03 2002-11-15 Avigen Inc Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen
GB0510057D0 (en) * 2005-05-17 2005-06-22 Glaxosmithkline Biolog Sa Novel device
ME03008B (me) * 2011-09-19 2018-10-20 Axon Neuroscience Se Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti
EP3044231B1 (en) * 2013-09-12 2020-08-05 BioMarin Pharmaceutical Inc. Aav vectors comprising a gene encoding factor viii
MY189674A (en) 2015-10-28 2022-02-24 Sangamo Therapeutics Inc Liver-specific constructs, factor viii expression cassettes and methods of use thereof
CN112770812A (zh) * 2018-07-24 2021-05-07 沃雅戈治疗公司 产生基因治疗制剂的系统和方法
US12497632B2 (en) * 2018-08-03 2025-12-16 Sangamo Therapeutics, Inc. Clinical parameters by expression of factor VIII
US12478553B2 (en) * 2018-11-13 2025-11-25 Sio2 Medical Products, Llc Polymer vials with substantially flat bottoms and injection stretch blow molding methods for making the same
BR112021009370A2 (pt) * 2018-11-14 2021-08-17 Regenxbio Inc. método de tratamento da doença de batten cln2, composição farmacêutica e kit
AU2019428629A1 (en) 2019-02-06 2021-01-28 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type I
WO2021071835A1 (en) * 2019-10-07 2021-04-15 Regenxbio Inc. Adeno-associated virus vector pharmaceutical composition and methods

Similar Documents

Publication Publication Date Title
JP2024500133A5 (https=)
ES2363600T3 (es) Formulación para medicamentos proteicos sin adición de seroalbumina humana (hsa).
CN116710149A (zh) 含有腺相关病毒载体的改善的药物组合物
BRPI0620316A2 (pt) formulações de proteìnas com viscosidades reduzida e seus usos
US11241486B2 (en) Treatment of Middle East respiratory syndrome coronavirus
AU2019376641A1 (en) Mini-nucleosome core proteins and use in nucleic acid delivery
UA123847C2 (uk) Рідка композиція анти-tnf альфа антитіла
US10918698B2 (en) Lyophilized pharmaceutical composition of Fc-peptide fusion protein
CN119072302A (zh) Aav药物产品的冻干制剂
AU2017225236B2 (en) A lyophilised pharmaceutical formulation and its use
US20240240204A1 (en) Methods and compositions for transport, storage, and delivery of adeno-associated viral vector and other molecules
US20220233657A1 (en) Treatment of middle east respiratory syndrome coronavirus
CN117298296A (zh) 一种重组腺相关病毒x载体制剂
AU2020395758B2 (en) Stable liquid formulations comprising a glucagon-like peptide 1 and uses thereof
WO2026030714A1 (en) Pharmaceutical compositions containing blood brain barrier penetrant aav capsids
CN121754692A (zh) 一种融合型腺相关病毒药物组合物及应用
AU2013224728A1 (en) Stabilized Compositions of Proteins Having a Free Thiol Moiety